Search:
This item requires a subscription.
The managed introduction of non-NICE cancer drugs BJCM, Volume 2, Number 3.
Obtaining access to new and expensive cancer drugs is a topic close to the hearts of cancer patients and the clinicians treating them. In England and Wales, the National Institute for Health and Clinical Excellence (NICE) has been making decisions on the availability of cancer drugs since 1999. Much has been written about the role of NICE and its perceived shortcomings.
To view this item, select one of the options below:
Purchase access
Sign in
email address
Password
Important
All the articles are in PDF format.
To view the articles you will need Adobe Acrobat Reader.
To download a copy, free of charge, please click here.